Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
May 31, 2024 08:36 ET
|
Ocugen
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 ...
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024 07:30 ET
|
Ocugen
Highlighting updates on OCU400 Phase 3 clinical trial starting early 2024 Featuring thought leaders in gene therapy and OCU400 Phase 1/2 clinical trial patient MALVERN, Pa., Feb. 14, 2024 ...